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BACKGROUND: Bisphosphanates are used primarily for the prevention and treatment of osteoporosis, and are also indicated for
osseous complications of malignancy. In addition to their bone resorption properties, the most commonly used nitrogen-containing
bisphosphonate compounds also inhibit protein prenylation, and thus may exert anti-tumour properties.
METHODS: To evaluate whether the use of these drugs may be associated with cancer, specifically breast cancer, we conducted a
population-based case–control study in Wisconsin from 2003 to 2006. Participants included 2936 incident invasive breast cancer
cases and 2975 population controls aged o70 years. Bisphosphonate use and potential confounders were assessed by interview.
RESULTS: Using multivariable logistic regression, the odds ratio for breast cancer in current bisphosphonate users compared with non-
users was 0.67 (95% confidence interval 0.51–0.89). Increasing duration of use was associated with a greater reduction in risk
(P-trend¼0.01). Risk reduction was observed in women who were not obese (P-interaction¼0.005).
CONCLUSION: These results are suggestive of an additional benefit of the common use of bisphosphonates, in this instance, the
reduction in breast cancer risk.
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Bisphosphonates are commonly prescribed for the prevention and
treatment of osteoporosis (Rosen, 2005). By inhibiting bone
resorption, bisphosphonate therapy also reduces skeletal compli-
cations from bone involvement in breast, prostate, and other
cancers, and from the bone-depleting consequences of some
treatments (Berenson et al, 1996; Aapro et al, 2008; Saad et al,
2008). In addition to the reduction in osteoclastic bone resorption,
the more potent aminobisphosphonates inhibit the mevalonate
pathway, thereby affecting cell function and survival(Luckman
et al, 1998; Dunford et al, 2001). As this pathway leads to the
prenylation of key signalling proteins required by all cells,
aminobisphosphonates may affect the viability of other cell types,
such as tumours (Russell et al, 1999; Caraglia et al, 2006).
Nitrogen-containing bisphosphonates have also been shown to
directly induce tumour apoptosis, inhibit angiogenesis, and
prevent tumour cell adhesion (Neville-Webbe et al, 2002; Wood
et al, 2002). These anti-proliferative actions may be relevant to the
development of a broad range of cancers, including breast
neoplasms(Green, 2003; Winter et al, 2008). We examined the
association between bisphosphonate use and breast cancer in a
population-based case–control study.
MATERIALS AND METHODS
Women aged 20–69 years with a new diagnosis of invasive breast
cancer from 2003 to 2006 were identified from Wisconsin’s
mandatory cancer registry (Sprague et al, 2008; Wernli et al, 2009).
For comparison, similarly aged community women without a
personal history of breast cancer were randomly selected from
driver’s licence lists. The study included 2988 breast cancer cases
(74% of eligible) and 3004 controls (67% of eligible). Women were
invited to participate in a structured interview to ascertain the use
of bisphosphonates, type of drug, duration and recency of use, as
well as physician diagnosis of osteoporosis, history of fractures,
height change since the age of 18 years, and other risk factors for
breast cancer. Exposure information was limited to events before a
reference date that was defined as the date of diagnosis for cases
and, for comparability, the date approximately 1 year before
interview for control women. The study was approved by the
University of Wisconsin-Madison institutional review board.
Multivariable logistic regression models were used to estimate
odds ratios and 95% confidence intervals and tests for linear trend
across ordinal values of categorical variables. Current use of
bisphosphonates was defined as use in the year before the
reference year, and former users had taken bisphosphonates at
any time before this period. Duration of use was the sum of all
periods of bisphosphonate use in the year before the reference
period. Analyses were adjusted for potentially confounding
variables selected a priori: age at reference date, year of interview,
parity (0–1, 2, 3, 4þ), age at first birth (nulliparous, o20, 20–24,
25–29, 30þ), first-degree family history of breast cancer, body
mass index 1 year before reference date (o24.9, 25–29.9,
Received 19 October 2009; revised 24 December 2009; accepted 5
January 2010; published online 16 February 2010
*Correspondence: Dr PA Newcomb; E-mail: pnewcomb@fhcrc.org
British Journal of Cancer (2010) 102, 799–802
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sX30kgm
–2), menopausal status, age at menopause (o45, 45–49,
50–54, 55þ), screening mammograms over the past 5 years
(0, 1–4, X5), a physician diagnosis of osteoporosis, smoking
status, and height change from the age of 18 years. Effect
modification was evaluated by inclusion of cross-product interac-
tion terms in logistic models. Owing to missing or incomplete
information on osteoporosis medications or their indications, 26
breast cancer cases and 29 control women were excluded, leaving
2936 cases and 2975 controls for analysis.
RESULTS
The average age at the reference date for breast cancer cases was
54.2 years (s.d.¼8.9 years) and for controls it was 54.8 years
(8.9 years). As expected, women with breast cancer were more
likely than controls to have a family history of breast cancer, a
college degree, to be older at first birth or nulliparous, to have
gained more weight since the age of 18 years, and to use
postmenopausal hormones; controls were more likely to report a
physician’s diagnosis of osteoporosis (data not shown).
Bisphosphonates were more commonly used by controls than by
cases; the multivariate-adjusted odds ratio for ever use was 0.70
(95% confidence interval 0.54–0.92; Table 1), which was similar to
the age-adjusted odds ratio, suggesting that the influence of
confounding was limited. The reduction in risk was significant
only among current users of bisphosphonates, although few
women were former users at the reference date. Increasing
duration of use was associated with greater reductions in breast
cancer risk (P-trend¼0.01).
To evaluate whether the inverse effects of bisphosphonates were
attributable to the medications themselves or to the conditions for
which they were prescribed, we examined use according to fracture
history (excluding women diagnosed with distant disease), height
loss, and physician-diagnosed osteoporosis. There was a sugges-
tion that use of bisphosphonates was associated with a reduced
risk of breast cancer only among women reporting symptoms of
bone loss (postmenopausal fractures, osteoporosis, and height
loss), but the differences were not statistically significant
(P-interaction¼0.29). The inverse effect of bisphosphonates
seemed limited to women who were not obese (P-inter-
action¼0.005, Figure 1). There were no statistical interactions
between bisphosphonates and age, smoking, or hormone therapy
(data not shown).
CONCLUSION
In this case–control study, use of bisphosphonates was associated
with approximately a 30% reduction in breast cancer risk, and this
decrease in risk was greatest for longer durations of use, and
among leaner women. This association was not attributed to the
primary indication for use, bone density loss, or fractures, which
we and others have previously shown as a risk factor for breast
Table 1 Odds ratios (ORs) (95% confidence intervals, CIs) of breast cancer associated with bisphosphonate use
Cases (N¼2936) Controls (N¼2975) Age adjusted Multivariable adjusted
Bisphosphonate use N (%) N (%) OR (95% CI)
a OR (95% CI)
b
Never use 2808 (95.6) 2788 (93.7) 1.00 (Referent) 1.00 (Referent)
Ever use 128 (4.4) 187 (6.2) 0.70 (0.56–0.89) 0.70 (0.54–0.92)
Former 22 (0.7) 26 (0.9) 0.85 (0.48–1.51) 0.91 (0.50–1.64)
Current 106 (3.6) 161 (5.4) 0.68 (0.53–0.88) 0.67 (0.51–0.89)
Duration of use (months)
3–12 58 (2.0) 76 (2.5) 0.78 (0.55–1.11) 0.78 (0.54–1.12)
13–24 26 (0.9) 37 (1.2) 0.72 (0.44–1.20) 0.69 (0.41–1.17)
X25 44 (1.5) 74 (2.5) 0.61 (0.42–0.90) 0.63 (0.42–0.95)
P-trend 0.01 0.01
aAdjusted for age at diagnosis.
bAdditionally adjusted for parity, age at first live birth, family history of breast cancer, body mass index, menopausal status, age at menopause, type
of hormone use, mammography, osteoporosis, smoking history, and height change.
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Figure 1 Odds ratios and 95% confidence intervals of breast cancer according to bisphosphonate use and body mass index (BMI). Odds ratios were
adjusted for age at diagnosis, party, age at first live birth, family history of breast cancer, BMI menopausal status, age at menopause, type of hormone use,
mammography, osteoporosis, smoking history, and height change. P-interaction for BMI and use of bisphosphonates¼0.005.
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2004). Our confidence in these results is strengthened by the large
size of the study, the population-based sampling, our considera-
tion of important confounders such as body mass index and
postmenopausal hormone use, and the generally high reliability
and validity of self-reports of medication use (Lipworth et al, 2001;
Boudreau et al, 2004, 2005).
There are limited data that directly support our epidemiological
findings. However, a number of observations may be relevant to a
protective effect of these medications on breast cancer incidence.
In animals bearing breast cancer xenografts, bisphosphonates
block the growth of bone metastases, and also extraskeletal disease
(Senaratne et al, 2000; Hiraga et al, 2001). Indeed, direct
cytotoxicity seen in vitro (Fromigue et al, 2000) may account for
some of the clinical benefit in patients taking bisphosphonates,
specifically aminobisphosphonates (Neville-Webbe et al, 2002;
Green, 2003; Caraglia et al, 2004). Although the molecular
targets of bisphosphonates are not fully known, several phases of
tumour growth and progression seem to be influenced (Neville-
Webbe et al, 2002; Wood et al, 2002; Caraglia et al, 2006). In a
recent clinical trial of early-stage breast cancer, nitrogen-contain-
ing bisphosphonates seemed to improve long-term outcomes
(Gnant et al, 2009), and several large clinical trials are currently
underway to clarify this issue (Bedard et al, 2009). Our finding
that bisphosphonates were not associated with breast cancer
risk reductions in obese women suggests that their inhibitory
actions may be related to some threshold effect of hormonal or
other growth factors; these are important aetiological exposures in
breast cancer (Hankinson et al, 2004). Thus, the pluripotent
actions of bisphosphonates are consistent with our observed
findings.
Unmeasured or unknown confounding factors may have been
present, for which adjustment was not possible. Although we
inquired about clinical symptoms and reports of physician-
diagnosed osteoporosis, bone mineral density was not available.
Nearly all users had used aminobisphosphonates (97% of users);
therefore, we could not evaluate specific types of preparations that
have very different mechanisms of action (Russell and Rogers,
1999; Bedard et al, 2009). Sample size was also too modest to
evaluate other breast cancer subgroups that may experience
different responses to bisphosphonates, such as specific histolo-
gical type or hormone receptor status. Finally, because the study
population was limited to women under the age of 70 years, the
prevalence of bisphosphonate use was lower than might be
expected in older women with clinical osteoporosis.
In summary, this study provides new evidence that the use of
bisphosphonates is associated with a potentially important
reduction in breast cancer risk. Because we were able to account
for important confounders, these findings may reflect real benefits
due to the anti-tumour mechanisms of these medications.
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